181 related articles for article (PubMed ID: 34124783)
1. AZD8055 enhances in vivo efficacy of afatinib in chordomas.
Zhao T; Siu IM; Williamson T; Zhang H; Ji C; Burger PC; Connis N; Ruzevick J; Xia M; Cottone L; Flanagan AM; Hann CL; Gallia GL
J Pathol; 2021 Sep; 255(1):72-83. PubMed ID: 34124783
[TBL] [Abstract][Full Text] [Related]
2. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Scheipl S; Barnard M; Cottone L; Jorgensen M; Drewry DH; Zuercher WJ; Turlais F; Ye H; Leite AP; Smith JA; Leithner A; Möller P; Brüderlein S; Guppy N; Amary F; Tirabosco R; Strauss SJ; Pillay N; Flanagan AM
J Pathol; 2016 Jul; 239(3):320-34. PubMed ID: 27102572
[TBL] [Abstract][Full Text] [Related]
3. Drug combination screening as a translational approach toward an improved drug therapy for chordoma.
Scheipl S; Barnard M; Lohberger B; Zettl R; Brcic I; Liegl-Atzwanger B; Rinner B; Meindl C; Fröhlich E
Cell Oncol (Dordr); 2021 Dec; 44(6):1231-1242. PubMed ID: 34550531
[TBL] [Abstract][Full Text] [Related]
4. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.
Magnaghi P; Salom B; Cozzi L; Amboldi N; Ballinari D; Tamborini E; Gasparri F; Montagnoli A; Raddrizzani L; Somaschini A; Bosotti R; Orrenius C; Bozzi F; Pilotti S; Galvani A; Sommer J; Stacchiotti S; Isacchi A
Mol Cancer Ther; 2018 Mar; 17(3):603-613. PubMed ID: 29237806
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
6. Synergistic drug combinations and machine learning for drug repurposing in chordoma.
Anderson E; Havener TM; Zorn KM; Foil DH; Lane TR; Capuzzi SJ; Morris D; Hickey AJ; Drewry DH; Ekins S
Sci Rep; 2020 Jul; 10(1):12982. PubMed ID: 32737414
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib inhibits growth of a patient-derived chordoma xenograft.
Siu IM; Ruzevick J; Zhao Q; Connis N; Jiao Y; Bettegowda C; Xia X; Burger PC; Hann CL; Gallia GL
PLoS One; 2013; 8(11):e78895. PubMed ID: 24260133
[TBL] [Abstract][Full Text] [Related]
8. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.
Yang LY; Cheng ZJ; Liu Z; Wang D; Zhang N; Fan ZL; Cai HQ; Zhang Y; Cai Y; Xu X; Wang JH; Du GH; Hao JJ; Wang MR
J Gastroenterol Hepatol; 2021 Sep; 36(9):2513-2522. PubMed ID: 33721913
[TBL] [Abstract][Full Text] [Related]
9. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
10. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
12.
Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial approaches targeting the EGFR family and c-Met in SCCHN.
Wang D; Lu Y; Nannapaneni S; Griffith CC; Steuer C; Qian G; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; He X; Chen ZG; Saba NF
Oral Oncol; 2021 Jan; 112():105074. PubMed ID: 33142224
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
16. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
17. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models.
Yee PS; Zainal NS; Gan CP; Lee BKB; Mun KS; Abraham MT; Ismail SM; Abdul Rahman ZA; Patel V; Cheong SC
Target Oncol; 2019 Apr; 14(2):223-235. PubMed ID: 30806895
[TBL] [Abstract][Full Text] [Related]
19. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
[TBL] [Abstract][Full Text] [Related]
20. Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.
Michmerhuizen NL; Owen JH; Heft Neal ME; Mann JE; Leonard E; Wang J; Zhai J; Jiang H; McHugh JB; Brenner JC; Prince MEP
J Neurooncol; 2020 Mar; 147(1):25-35. PubMed ID: 32067197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
